Taking Psychedelics Seriously

Ira Byock, Ira Byock

Abstract

Background: Psychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. More recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored approach. A single or brief series of sessions often results in substantial and sustained improvement among people with treatment-resistant depression and anxiety, including those with serious medical conditions. Need and Clinical Considerations: Palliative care clinicians occasionally encounter patients with emotional, existential, or spiritual suffering, which persists despite optimal existing treatments. Such suffering may rob people of a sense that life is worth living. Data from Oregon show that most terminally people who obtain prescriptions to intentionally end their lives are motivated by non-physical suffering. This paper overviews the history of this class of drugs and their therapeutic potential. Clinical cautions, adverse reactions, and important steps related to safe administration of psychedelics are presented, emphasizing careful patient screening, preparation, setting and supervision.

Conclusion: Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent suffering and growing acceptance of physician-hastened death as a medical response, it is time to revisit the legitimate therapeutic use of psychedelics.

Keywords: MDMA; depression; existential suffering; palliative care patients; pharmaco-assisted therapy; post-traumatic stress disorder; psilocybin; psychedelic drugs; therapeutic use.

Conflict of interest statement

No competing financial interests exist.

References

    1. Griffiths RR, Johnson MW, Carducci MA, et al. : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30:1181–1197
    1. Grob CS, Danforth AL, Chopra GS, et al. : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68:71–78
    1. Johnson MW, Griffiths RR: Potential therapeutic effects of psilocybin. Neurotherapeutics 2017;14:734–740
    1. Carhart-Harris RL, Roseman L, Bolstridge M, et al. : Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 2017;7:13187.
    1. Pollan M: The Treatment Trip. The New Yorker, February 9, 2015
    1. Bone E: Can Mushrooms Treat Depression? The New York Times; November 29, 2014; Sunday Review
    1. Dean J: How MDMA went from club drug to “Breakthrough Therapy.” Wall St J 2017
    1. Grof S: LSD Psychotherapy. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies, 1980
    1. Huxley A: The Doors of Perception. Harper & Brothers, New York, 1954
    1. Masters REL, Houston J: The Varieties of Psychedelic Experience. Dell Publishing, New York, 1966
    1. Griffths RR, Grob CS: Hallucinogens as medicine. Sci Am 2010;303:76–79
    1. Kast E: LSD and the dying patient. Chic Med Sch Q 1966;26:80–87
    1. Pahnke WN, Kurland AA, Unger S, et al. : The experimental use of psychedelic (LSD) psychotherapy. JAMA 1970;212:1856–1863
    1. Iglewicz A, Morrison K, Nelesen RA, et al. : Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases. Psychosomatics 2015;56:329–337
    1. Irwin SA, Iglewicz A, Nelesen RA, et al. : Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. J Palliat Med 2013;16:958–965
    1. Swiatek KM, Jordan K, Coffman J: New use for an old drug: Oral ketamine for treatment-resistant depression. BMJ Case Rep 2016;2016: pii:
    1. Mithoefer MC, Grob CS, Brewerton TD: Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. Lancet Psychiatry 2016;3:481–488
    1. Sessa B: MDMA and PTSD treatment: “PTSD: From novel pathophysiology to innovative therapeutics”. Neurosci Lett 2017;649:176–180
    1. Quill TE, Byock IR: Responding to intractable terminal suffering: The role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132:408–414
    1. Kissane DW, Clarke DM, Street AF: Demoralization syndrome—A relevant psychiatric diagnosis for palliative care. J Palliat Care 2001;17:12–21
    1. Kissane DW: The relief of existential suffering. Arch Intern Med 2012;172:1501–1505
    1. National Institute of Mental Health: Suicide. 2017. (Last accessed October21, 2017)
    1. Prevention AFfS: Suicide Statistics. 2017. (Last accessed October19, 2017)
    1. Oregon PHD: Death with Dignity Act Annual Reports. 2017. (Last accessed April12, 2017)
    1. Carhart-Harris RL, Erritzoe D, Haijen E, et al. : Psychedelics and connectedness. Psychopharmacology (Berl) 2017. [Epub ahead of print]; DOI:10.1007/s00213-017-4701-y
    1. Ruck CA, Bigwood J, Staples D, et al. : Entheogens. J Psychedelic Drugs 1979;11:145–146
    1. Wagner MT, Mithoefer MC, Mithoefer AT, et al. : Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol 2017;31:967–974
    1. Williams A: How LSD Saved One Woman's Marriage. New York Times, January 7, 2017
    1. Waldman A: A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life. Alfred A. Knopf, New York, 2017
    1. Boire RG. The Politics of Medicine: The Scheduling of MDMA. 2000. (Last accessed October8, 2017)
    1. Jones DA, Paton D: How does legalization of physician-assisted suicide affect rates of suicide? South Med J 2015;108:599–604
    1. Kheriaty A: Social contagion effects of physician-assisted suicide: Commentary on “How Does Legalization of Physician-Assisted Suicide Affect Rates of Suicide?”. South Med J 2015;108:605–606
    1. Jonhson BE, Heine MJ: What patients should know about Pa.'s new ‘right to try’ legislation. The Inquirer, October 19, 2017
    1. Simmons Z. Right-to-try investigational therapies for incurable disorders. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1451–1457
    1. Weintraub K: Novel system to get dying patients an experimental cancer drug raises hopes—And thorny questions. STAT News, 2016
    1. Miller JE, Ross JS, Moch KI, Caplan AL: Characterizing expanded access and compassionate use programs for experimental drugs. BMC Res Notes 2017;10:350.
    1. Cohen-Kurzrock BA, Cohen PR, Kurzrock R: Health policy: The right to try is embodied in the right to die. Nat Rev Clin Oncol 2016;13:399–400
    1. Goldsmith G: Personal communication, March 2, 2017

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe